Nuo Q3 Revenue Jumps 81% to $1.87M, But Going Concern Doubt Persists on $81K Cash
AURX sits 42% above its 52-week low of $0.77 on light trading volume (0.1× avg).
Summary
Nuo Therapeutics grew Q3 revenue 81% to $1.87M and cut its quarterly loss to $424,928, but cash is down to $80,941 and management reiterates substantial doubt about continuing as a going concern, with a Pfizer reagent back order threatening Aurix supply into 2027.
Key Events · Earnings and Guidance · AURX
-
Q3 Revenue Up 81% to $1.87M
Total revenue was $1,866,125 versus $1,032,096 a year earlier, with product sales of $1,779,563 up from $957,096. Nine-month revenue reached $4,937,226 versus $2,216,679.
-
Loss Narrows but Cash Dwindles
Q3 net loss was $424,928 versus $537,919; nine-month net loss was $1,320,995 versus $1,933,736. Cash fell to $80,941 at September 30, 2026 from $548,946 at December 31, 2025.
-
Going Concern Doubt Reiterated
Management states current resources and projected Aurix and Smith+Nephew revenue are insufficient to support operations for the next 12 months, and that substantial doubt about going concern exists.
-
Pfizer Reagent Back Order Threatens Supply
Thrombin-JMI was on back order by Q3 2026 with resupply estimated for Q2 2027, causing a roughly two-week Aurix stockout in early August 2026; only short-term alternative thrombin supply has been secured.
Analysis · AURX · Industrial Applications And Services
Revenue is compounding fast: Q3 product sales of $1.78M are up 86% year over year, nine-month revenue of $4.94M is up 127%, and the quarterly net loss narrowed to $424,928 from $537,919. The balance sheet, however, is the story. Cash fell to $80,941 from $548,946 at year-end, and management states plainly that current resources plus projected Aurix and Smith+Nephew revenue are insufficient to fund the next 12 months. Funding comes from 12% secured notes, fully drawn at $2.0M after the October 6, 2026 Second Funding, with interest paid in warrants rather than cash and principal amortization starting March 31, 2027. Layered on top is a supply problem: Pfizer's Thrombin-JMI is on back order with resupply estimated for Q2 2027, which caused a roughly two-week Aurix stockout in early August 2026; management says it has short-term alternative thrombin but no long-term solution. The previously disclosed material weakness in internal controls remains unremediated.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AURX was trading at $1.09 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $52.8M. The 52-week trading range was $0.77 to $3.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.